Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actionsDiscusses the pathways of metabolism (by CYP2D6 and MAO-A) and how co-administration with MAO inhibitors changes exposure.

The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptorsA lab study showing how 5-MeO-DMT affects cortical oscillations via 5-HT1A and 5-HT2A receptors in mice — evidence of region-specific brain modulation.

5-MeO-DMT induces sleep-like LFP spectral signatures in the hippocampus and prefrontal cortex of awake ratsRodent research indicating that 5-MeO-DMT alters hippocampal and prefrontal cortexfield potentials, possibly relevant to memory/learning functions.

The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumptionA large online survey (n ~515) capturing usage patterns, mystical experience intensities, addiction potential, and self-reported psychiatric symptom change.

Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trialsA systematic review of clinical trials reporting safety outcomes, tolerability, and short-term effects; concludes a favorable short-term safety profile without serious adverse events to date.

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled studyA randomized, double-blind, placebo-controlled clinical study examining repeated low doses in adults with moderate depressive/anxiety symptoms; early evidence for safety and tolerability with pharmacokinetic data.

Structural pharmacology and therapeutic potential of 5-methoxytryptaminesExamines structure–activity relationships of 5-methoxy tryptamines at serotonin receptors and implications for therapeutic design (e.g., compounds that retain potential benefit without hallucinogenic effects).

A research institution page summarizing active and completed clinical studies (Phase I/early human safety & pharmacokinetics).

A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate GyrusA controlled animal study (rats) showing that one intracerebroventricular injection of 5-MeO-DMT significantly increased neurogenesis (BrdU+ cells), accelerated neuron maturation, and changed electrophysiological properties of new neurons in the dentate gyrus—suggesting mechanisms that could underlie mood improvement effects.

The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptorsWhile the specific article you referenced by title is not currently indexed in PubMed with that exact phrasing, you can cite its functional core finding through related articles showing that 5-MeO-DMT affects neural oscillatory activity and regional brain activation in rodents, implicating 5-HT receptor subtypes in sensory and thalamic circuits. A representative example (similar content) is here:

Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMTIn vitro study on human cerebral organoids showing that 5-MeO-DMT exposure alters the expression of hundreds of proteins associated with cytoskeletal reorganization, dendritic spine formation, and long-term potentiation pathways. These findings provide a cellular/molecular basis for potential neuroplastic effects.

A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorderThis is not a randomized trial — it reports on one individual treated with sequential psychedelic therapy using ibogaine followed by 5-MeO-DMT, paired with pre- and post-treatment SPECT scans.